Experimental 'Living Drug' tested as last hope for tough lymphomas
NCT ID NCT04067414
Summary
This study tested a new type of personalized immune therapy called BZ019 (a CAR-T cell therapy) in adults with aggressive B-cell lymphomas that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the therapy could shrink tumors. Participants had their own immune cells collected, genetically modified to target their cancer, and then infused back after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.